Elevation Oncology, Inc. today announced that members of management will participate in upcoming investor conferences in March.
| BOSTON, Feb. 28, 2024 /PRNewswire/ -- Elevation Oncology Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that members of management will participate in upcoming investor conferences in March:
A live webcast and replay of the fireside chat at the TD Cowen 44th Annual Health Care Conference will be available on the Events page of the Company’s Investor Relations website at https://investors.elevationoncology.com. About Elevation Oncology, Inc. Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are rethinking drug development by seeking out innovative, selective cancer therapies that can be matched to a patient’s unique tumor characteristics. Our lead candidate, EO-3021, is a potential best-in-class antibody drug conjugate (ADC) designed to target Claudin 18.2, a clinically validated molecular target. EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. We are evaluating EO-3021 in a Phase 1 study in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers. We are also exploring other opportunities through new or existing partnerships and business development opportunities to expand our oncology pipeline. For more information, visit www.ElevationOncology.com. Elevation Oncology Investor and Media Contact Candice Masse, 978-879-7273
SOURCE Elevation Oncology | ||
Company Codes: NASDAQ-NMS:ELEV |
View original content to download multimedia:
